Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to -$507000.0.

  • Relay Therapeutics' Change in Accured Expenses fell 14435.7% to -$507000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.2 million, marking a year-over-year decrease of 25172.89%. This contributed to the annual value of $10.3 million for FY2024, which is 14115.76% up from last year.
  • According to the latest figures from Q3 2025, Relay Therapeutics' Change in Accured Expenses is -$507000.0, which was down 14435.7% from -$953000.0 recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Change in Accured Expenses ranged from a high of $17.9 million in Q3 2022 and a low of -$19.5 million during Q3 2023
  • Moreover, its 5-year median value for Change in Accured Expenses was $3.1 million (2022), whereas its average is $668684.2.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first tumbled by 30380.05% in 2022, then surged by 68215.0% in 2024.
  • Relay Therapeutics' Change in Accured Expenses (Quarter) stood at $7.9 million in 2021, then crashed by 303.8% to -$16.1 million in 2022, then skyrocketed by 41.01% to -$9.5 million in 2023, then grew by 23.4% to -$7.3 million in 2024, then surged by 93.05% to -$507000.0 in 2025.
  • Its Change in Accured Expenses stands at -$507000.0 for Q3 2025, versus -$953000.0 for Q2 2025 and -$3.4 million for Q1 2025.